EP4712963A2 - Kleinmolekülige p27-hemmer - Google Patents
Kleinmolekülige p27-hemmerInfo
- Publication number
- EP4712963A2 EP4712963A2 EP24808047.5A EP24808047A EP4712963A2 EP 4712963 A2 EP4712963 A2 EP 4712963A2 EP 24808047 A EP24808047 A EP 24808047A EP 4712963 A2 EP4712963 A2 EP 4712963A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- pharmaceutically acceptable
- group
- acceptable salt
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363467561P | 2023-05-18 | 2023-05-18 | |
| PCT/US2024/029543 WO2024238709A2 (en) | 2023-05-18 | 2024-05-15 | Small molecule inhibitors of p27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4712963A2 true EP4712963A2 (de) | 2026-03-25 |
Family
ID=93520146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP24808047.5A Pending EP4712963A2 (de) | 2023-05-18 | 2024-05-15 | Kleinmolekülige p27-hemmer |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP4712963A2 (de) |
| CN (1) | CN121548417A (de) |
| AU (1) | AU2024271540A1 (de) |
| WO (1) | WO2024238709A2 (de) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1807081A1 (de) * | 2004-10-29 | 2007-07-18 | Janssen Pharmaceutica N.V. | Cyclohexyldiamine als selektive alpha-1a/1d-adrenorezeptor-antagonisten zur behandlung von benigner prostata-hypertrophie und symptomen der unteren harnwege |
| TWI598337B (zh) * | 2009-06-29 | 2017-09-11 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| ES2642109T3 (es) * | 2009-12-09 | 2017-11-15 | Agios Pharmaceuticals, Inc. | Compuestos terapéuticamente activos para su uso en el tratamiento de cáncer caracterizados por tener una mutación de IDH |
| WO2014207508A1 (en) * | 2013-06-27 | 2014-12-31 | Piramal Enterprises Limited | Pyridyl compound suitable for the treatment of metabolic disorders |
| BR112017002260A2 (pt) * | 2014-08-07 | 2017-11-21 | Vitae Pharmaceuticals Inc | derivados de piperazina como moduladores do receptor x do fígado |
-
2024
- 2024-05-15 EP EP24808047.5A patent/EP4712963A2/de active Pending
- 2024-05-15 AU AU2024271540A patent/AU2024271540A1/en active Pending
- 2024-05-15 CN CN202480042388.3A patent/CN121548417A/zh active Pending
- 2024-05-15 WO PCT/US2024/029543 patent/WO2024238709A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024238709A3 (en) | 2025-05-30 |
| CN121548417A (zh) | 2026-02-17 |
| AU2024271540A9 (en) | 2025-12-11 |
| WO2024238709A2 (en) | 2024-11-21 |
| AU2024271540A1 (en) | 2025-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7191828B2 (ja) | がん治療のための組成物および方法 | |
| KR102111704B1 (ko) | Iap 단백질의 2가 억제제 및 그를 사용하는 치료 방법 | |
| EP2427441B1 (de) | Pkm2-modulatoren zur krebsbehandlung | |
| CN105008351B (zh) | Cdc7抑制剂 | |
| CN114980976A (zh) | 共价ras抑制剂及其用途 | |
| EP2655350B1 (de) | Bicyclische pkm2-aktivatoren | |
| CA2823401A1 (en) | Therapeutic compounds and compositions | |
| CN107108567A (zh) | 极光激酶a抑制剂 | |
| WO2012167415A1 (zh) | 嘧啶并嘧啶酮类化合物及其药用组合物和应用 | |
| CN101723936A (zh) | 激酶抑制剂及其在药学中的用途 | |
| AU2024360599A1 (en) | Pyrrolo[2,1-f][1,2,4]triazine compounds acting against cancers, inflammatory diseases, and fibrotic disease via interaction with ras superfamily proteins | |
| US20240132485A1 (en) | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof | |
| CN105611930A (zh) | 作为非凋亡调控性细胞死亡抑制剂的螺环喹喔啉衍生物 | |
| CN108348779A (zh) | Ack1/tnk2酪氨酸激酶的抑制剂 | |
| CN108368143A (zh) | 用于癌症疗法的单马来酰亚胺官能化的铂化合物 | |
| CN111093651A (zh) | Ido抑制剂的无定形和结晶形式 | |
| TW201922709A (zh) | 表皮生長因子受體抑制劑 | |
| AU2024271540A9 (en) | Small molecule inhibitors of p27 | |
| WO2023203172A1 (en) | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof | |
| CN113773273B (zh) | 苯并异噻唑类化合物及其制备方法和用途 | |
| WO2022148821A1 (en) | Usp7 binding survival-targeting chimeric (surtac) molecules & uses thereof | |
| WO2025223477A1 (zh) | 并环含氮化合物、其晶型及其制备方法和用途 | |
| CN115707702A (zh) | Rad51抑制剂化合物的晶型及其应用 | |
| HK40100861A (zh) | 结晶形式、含有该结晶形式的组合物及使用它们的方法 | |
| HK40074236A (en) | Covalent ras inhibitors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20251128 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR |